A group paper in association with UT scholars

25 March 2021 | 13:23 Code : 15572 News
visits:68

Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems.

Mar 22, 2021

Glioblastoma multiforme (GBM) is one of the worst brain tumors arising from glial cells, causing many deaths annually. Surgery, chemotherapy, radiotherapy and immunotherapy are used for GBM treatment. However, GBM is still an incurable disease, and new approaches are required for its successful treatment. Because mutations and amplifications occurring in several genes are responsible for the progression and aggressive behavior of GBM cells, genetic approaches are of great importance in its treatment. Small interfering RNA (siRNA) is a new emerging tool to silence the genes responsible for disease progression, particularly cancer. SiRNA can be used for GBM treatment by down-regulating genes such as VEGF, STAT3, ELTD1 or EGFR. Furthermore, the use of siRNA can promote the chemosensitivity of GBM cells. However, the efficiency of siRNA in GBM is limited by its degradation by enzymes, and its off-targeting effects. SiRNA-loaded carriers, especially nanovehicles that are ligand-functionalized by CXCR4 or angiopep-2, can be used for the protection and targeted delivery of siRNA. Nanostructures can provide a platform for co-delivery of siRNA plus anti-tumor drugs as another benefit. The prepared nanovehicles should be stable and biocompatible in order to be tested in human studies.  

 Published by Elsevier Inc.

References

PubMed

ABOUT THE AUTHOR

Sepideh Mirzaei,Mahmood Khaksary Mahabady,Amirhossein Zabolian,Alireza Abbaspour,Peyman Fallahzadeh,Maedeh Noori,Farid Hashemi,Kiavash Hushmandi,Salman Daneshi,Alan Prem Kumar,Amir Reza Aref,Saeed Samarghandian,Pooyan Makvandi,Haroon Khan,Michael R Hamblin,Milad Ashrafizadeh,Ali Zarrabi

Sepideh Mirzaei

·  Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran.

Mahmood Khaksary Mahabady

·  Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.

Amirhossein Zabolian

·  Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

Alireza Abbaspour

·  Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.

Peyman Fallahzadeh

·  Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.

Maedeh Noori

·  Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

Farid Hashemi

·  Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.

Kiavash Hushmandi

·  Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.

Salman Daneshi

·  Department of Public Health, School of Health, Jiroft University of Medical Sciences, Jiroft, Iran.

Alan Prem Kumar

·  Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore.

Amir Reza Aref

·  Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Translational Sciences, Xsphera Biosciences Inc., Boston, MA, USA.

Saeed Samarghandian

·  Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. Electronic address: samarghandians@mums.ac.ir.

Pooyan Makvandi

·  Centre for Micro-BioRobotics, Istituto Italiano di Tecnologia, viale Rinaldo Piaggio 34, 56025 Pontedera, Pisa, Italy.

Haroon Khan

·  Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan.

Michael R Hamblin

·  Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa. Electronic address: hamblin.lab@gmail.com.

Milad Ashrafizadeh

·  Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Üniversite Caddesi No. 27, Orhanlı, Tuzla, 34956 Istanbul, Turkey; Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, 34956 Istanbul, Turkey. Electronic address: milad.ashrafizadeh@sabanciuniverisity.edu.

Ali Zarrabi

·  Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, 34956 Istanbul, Turkey.

Courtesy of Physician’s Weekly and Science Direct :

https://www.physiciansweekly.com/small-interfering-rna-sirna-to-target-genes-and-molecular-pathways-in-glioblastoma-therapy-current-status-with-an-emphasis-on-delivery-systems/

https://www.sciencedirect.com/science/article/abs/pii/S0024320521003532


Your Comment :